Lower limb ischemic disease (LEAD) affects a significant portion of the population, with most patients being asymptomatic. Patient screening is necessary because LEAD patients have an increased risk of occurrence of other cardiovascular events and manifestations of disease, in terms of leg symptoms such as intermittent claudication, critical limb ischemia, or amputation. The aim of this work was to evaluate the cost-effectiveness of screening using ABI diagnostics in asymptomatic patients and its impact on limb symptoms associated with LEAD. A discrete event simulation model was created to capture lifetime costs and effects. Costs were calculated from the perspective of the health care payer, and the effects were calculated as QALYs. A cost-effectiveness analysis was performed to compare ABI screening examination and the situation without such screening. A probabilistic sensitivity analysis and scenario analysis were carried out to evaluate the robustness of the results. In the basic setting, the screening intervention was a more expensive intervention, at a cost of CZK 174,010, compared to CZK 70,177 for the strategy without screening. The benefits of screening were estimated at 14.73 QALYs, with 14.46 QALYs without screening. The final ICER value of CZK 389,738 per QALY is below the willingness to pay threshold. Likewise, the results of the probabilistic sensitivity analysis and of the scenario analysis were below the threshold of willingness to pay, thus confirming the robustness of the results. In conclusion, ABI screening appears to be a cost-effective strategy for asymptomatic patients aged 50 years when compared to the no-screening option.

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague 272 01 Kladno Czech Republic

Zobrazit více v PubMed

Criqui M.H., Aboyans V. Epidemiology of Peripheral Artery Disease. Circ. Res. 2015;116:1509–1526. doi: 10.1161/CIRCRESAHA.116.303849. PubMed DOI

Fowkes F.G.R., Aboyans V., Fowkes F.J.I., McDermott M.M., Sampson U.K.A., Criqui M.H. Peripheral Artery Disease: Epidemiology and Global Perspectives. Nat. Rev. Cardiol. 2017;14:156–170. doi: 10.1038/nrcardio.2016.179. PubMed DOI

Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G.R. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J. Vasc. Surg. 2007;45:S5–S67. doi: 10.1016/j.jvs.2006.12.037. PubMed DOI

Criqui M.H., Matsushita K., Aboyans V., Hess C.N., Hicks C.W., Kwan T.W., McDermott M.M., Misra S., Ujueta F., on behalf of the American Heart Association Council on Epidemiology and Prevention et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement from the American Heart Association. Circulation. 2021;144:e171–e191. doi: 10.1161/CIR.0000000000001005. PubMed DOI PMC

Thiruvoipati T. Peripheral Artery Disease in Patients with Diabetes: Epidemiology, Mechanisms, and Outcomes. World J. Diabetes. 2015;6:961. doi: 10.4239/wjd.v6.i7.961. PubMed DOI PMC

Gerhard-Herman M.D., Gornik H.L., Barrett C., Barshes N.R., Corriere M.A., Drachman D.E., Fleisher L.A., Fowkes F.G.R., Hamburg N.M., Kinlay S., et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686–e725. doi: 10.1161/CIR.0000000000000470. PubMed DOI PMC

Diehm C., Allenberg J.R., Pittrow D., Mahn M., Tepohl G., Haberl R.L., Darius H., Burghaus I., Trampisch H.J. Mortality and Vascular Morbidity in Older Adults with Asymptomatic versus Symptomatic Peripheral Artery Disease. Circulation. 2009;120:2053–2061. doi: 10.1161/CIRCULATIONAHA.109.865600. PubMed DOI

Aboyans V., Ricco J.-B., Bartelink M.-L.E.L., Björck M., Brodmann M., Cohnert T., Collet J.-P., Czerny M., De Carlo M., Debus S., et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS) Eur. Heart J. 2018;39:763–816. doi: 10.1093/eurheartj/ehx095. PubMed DOI

McDermott M.M., Applegate W.B., Bonds D.E., Buford T.W., Church T., Espeland M.A., Gill T.M., Guralnik J.M., Haskell W., Lovato L.C., et al. Ankle Brachial Index Values, Leg Symptoms, and Functional Performance among Community-Dwelling Older Men and Women in the Lifestyle Interventions and Independence for Elders Study. JAHA. 2013;2:e000257. doi: 10.1161/JAHA.113.000257. PubMed DOI PMC

McDermott M.M., Mehta S., Liu K., Guralnik J.M., Martin G.J., Criqui M.H., Greenland P. Leg Symptoms, the Ankle-Brachial Index, and Walking Ability in Patients with Peripheral Arterial Disease. J. Gen. Intern. Med. 1999;14:173–181. doi: 10.1046/j.1525-1497.1999.00309.x. PubMed DOI PMC

McDermott M.M., Liu K., Greenland P., Guralnik J.M., Criqui M.H., Chan C., Pearce W.H., Schneider J.R., Ferrucci L., Celic L., et al. Functional Decline in Peripheral Arterial Disease: Associations with the Ankle Brachial Index and Leg Symptoms. JAMA. 2004;292:453. doi: 10.1001/jama.292.4.453. PubMed DOI

Fontaine R., Kim M., Kieny R. Surgical Treatment of Peripheral Circulation Disorders. Helv Chir Acta. 1954;21:499–533. PubMed

Karnon J., Stahl J., Brennan A., Caro J.J., Mar J., Möller J. Modeling Using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Value Health. 2012;15:821–827. doi: 10.1016/j.jval.2012.04.013. PubMed DOI

R Core Team . R: A Language and Environment for Statistical Computing. R Core Team; Vienna, Austria: 2021.

ČSÚ—Věková Struktura. [(accessed on 18 June 2022)]. Available online: https://www.czso.cz/staticke/animgraf/cz/index.html?lang=cz.

Pollak A.W., Norton P.T., Kramer C.M. Multimodality Imaging of Lower Extremity Peripheral Arterial Disease: Current Role and Future Directions. Circ. Cardiovasc. Imaging. 2012;5:797–807. doi: 10.1161/CIRCIMAGING.111.970814. PubMed DOI PMC

Ministerstvo Zdravotnictví . Čechům se Během Pandemie Zhoršil Zdravotní Stav, Odkládali Návštěvu Lékaře. Ministerstvo Zdravotnictví; Prague, Czech Republic: 2021.

Golledge J., Drovandi A. Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease. JAT. 2021;28:573–583. doi: 10.5551/jat.62778. PubMed DOI PMC

Bevan G.H., White Solaru K.T. Evidence-Based Medical Management of Peripheral Artery Disease. Arterioscler. Thromb. Vasc. Biol. 2020;40:541–553. doi: 10.1161/ATVBAHA.119.312142. PubMed DOI

Simpson E.L., Kearns B., Stevenson M.D., Cantrell A.J., Littlewood C., Michaels J.A. Enhancements to Angioplasty for Peripheral Arterial Occlusive Disease: Systematic Review, Cost-Effectiveness Assessment and Expected Value of Information Analysis. Health Technol. Assess. 2014;18:1–252. doi: 10.3310/hta18100. PubMed DOI PMC

Zdravotnictví M. Stažení Distribučního Balíčku CZ-DRG v4 Revize 1. Ministerstvo Zdravotnictví; Prague, Czech Republic: 2021.

Corro Ramos I., Hoogendoorn M., Rutten-van Mölken M.P.M.H. How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease. Med. Decis. Mak. 2020;40:619–632. doi: 10.1177/0272989X20932145. PubMed DOI PMC

Janssen M.F., Szende A., Cabases J., Ramos-Goñi J.M., Vilagut G., König H.H. Population Norms for the EQ-5D-3L: A Cross-Country Analysis of Population Surveys for 20 Countries. Eur. J. Health Econ. 2019;20:205–216. doi: 10.1007/s10198-018-0955-5. PubMed DOI PMC

de Vries M., Ouwendijk R., Kessels A.G., de Haan M.W., Flobbe K., Hunink M.G.M., van Engelshoven J.M.A., Nelemans P.J. Comparison of Generic and Disease-Specific Questionnaires for the Assessment of Quality of Life in Patients with Peripheral Arterial Disease. J. Vasc. Surg. 2005;41:261–268. doi: 10.1016/j.jvs.2004.11.022. PubMed DOI

Sculpher M., Michaels J., Mckenna M., Minor J. A Cost-Utility Analysis of Laser-Assisted Angioplasty for Peripheral Arterial Occlusions. Int. J. Technol. Assess. Health Care. 1996;12:104–125. doi: 10.1017/S0266462300009430. PubMed DOI

info@aion.cz, A.C.-428/2020 Sb Vyhláška o Stanovení Hodnot Bodu, Výše Úhrad Hrazených Služeb a Regulačních Omezení pro Rok. 2021. [(accessed on 29 May 2022)]. Available online: https://www.zakonyprolidi.cz/cs/2020-428.

Státní Ústav pro Kontrolu Léčiv. [(accessed on 29 May 2022)]. Available online: https://www.sukl.cz/modules/medication/search.php.

Klasnová N. Master’s Thesis. ČVUT, Fakulta Biomedicínského Inženýrství v Kladně; Kladno, Czech Republic: 2019. Ekonomická Náročnost Protetické a Terapeutické Péče Dolní Končetiny Po Transfemurální Amputaci.

Půlpán R. Úvodní Slovo. Ortop. Protet. Odb. Časopis Fed. Ortop. Protetiků Tech. Oborů. 2018;21:4–5.

Stryja J., Turoň J. Wound Healing—Cost-Eff Ectiveness Data from the Providers and Payers Viewpoint. Cesk. Slov. Neurol. N. 2017;80:113. doi: 10.14735/amcsnn2017S18. DOI

ÚZIS ČR . Zdravotnických Informací a Statistiky Zdravotnická Ročenka 2018. České Republiky; Prague, Czech Republic: 2018.

Wilkins E., Wilson L., Wickramasinghe K., Bhatnagar P., Leal J., Luengo-Fernandez R., Burns R., Rayner M., Townsend N. European Cardiovascular Disease Statistics 2017. European Heart Network; Brusel, Brussels: 2017.

Eddy D.M., Hollingworth W., Caro J.J., Tsevat J., McDonald K.M., Wong J.B. Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med. Decis. Mak. 2012;32:733–743. doi: 10.1177/0272989X12454579. PubMed DOI

Státní Ústav pro Kontrolu Léčiv SP-CAU-028—W: Postup pro Posuzování Analýzy Nákladové Efektivity 2022. [(accessed on 29 May 2022)]. Available online: https://www.sukl.cz/leciva/sp-cau-028.

Briggs A.H., Weinstein M.C., Fenwick E.A.L., Karnon J., Sculpher M.J., Paltiel A.D. Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group–6. Med. Decis. Mak. 2012;32:722–732. doi: 10.1177/0272989X12458348. PubMed DOI

Vaidya A., Joore M.A., ten Cate-Hoek A.J., ten Cate H., Severens J.L. Screen or Not to Screen for Peripheral Arterial Disease: Guidance from a Decision Model. BMC Public Health. 2014;14:89. doi: 10.1186/1471-2458-14-89. PubMed DOI PMC

Hirsch A.T. Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. JAMA. 2001;286:1317. doi: 10.1001/jama.286.11.1317. PubMed DOI

Sutkowska E.E., Sokołowski M., Zdrojowy K., Dragan S. Active Screening for Diabetic Foot—Assessment of Health Care Professionals’ Compliance to It. Clin. Diabetol. 2016;5:83–87. doi: 10.5603/DK.2016.0014. DOI

Aboyans V., Criqui M.H., Abraham P., Allison M.A., Creager M.A., Diehm C., Fowkes F.G.R., Hiatt W.R., Jönsson B., Lacroix P., et al. Measurement and Interpretation of the Ankle-Brachial Index: A Scientific Statement From the American Heart Association. Circulation. 2012;126:2890–2909. doi: 10.1161/CIR.0b013e318276fbcb. PubMed DOI

Johnston A.L., Vemulapalli S., Gosch K.L., Aronow H.D., Abbott J.D., Patel M.R., Smolderen K.G., Shishebor M., Spertus J.A., Jones W.S. Ankle-Brachial Index in Patients with Intermittent Claudication Is a Poor Indicator of Patient-Centered and Clinician-Based Evaluations of Functional Status. J. Vasc. Surg. 2019;69:906–912. doi: 10.1016/j.jvs.2018.07.039. PubMed DOI

Itoga N.K., Minami H.R., Chelvakumar M., Pearson K., Mell M.M., Bendavid E., Owens D.K. Cost-Effectiveness Analysis of Asymptomatic Peripheral Artery Disease Screening with the ABI Test. Vasc. Med. 2018;23:97–106. doi: 10.1177/1358863X17745371. PubMed DOI PMC

Lindholt J.S., Søgaard R. Clinical Benefit, Harm, and Cost Effectiveness of Screening Men for Peripheral Artery Disease: A Markov Model Based on the VIVA Trial. Eur. J. Vasc. Endovasc. Surg. 2021;61:971–979. doi: 10.1016/j.ejvs.2021.02.039. PubMed DOI

McDermott M.M., Guralnik J.M., Tian L., Liu K., Ferrucci L., Liao Y., Sharma L., Criqui M.H. Associations of Borderline and Low Normal Ankle-Brachial Index Values With Functional Decline at 5-Year Follow-Up. J. Am. Coll. Cardiol. 2009;53:1056–1062. doi: 10.1016/j.jacc.2008.09.063. PubMed DOI PMC

Karnon J., Haji Ali Afzali H. When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES. PharmacoEconomics. 2014;32:547–558. doi: 10.1007/s40273-014-0147-9. PubMed DOI

Lindholt J.S., Søgaard R. Population Screening and Intervention for Vascular Disease in Danish Men (VIVA): A Randomised Controlled Trial. Lancet. 2017;390:2256–2265. doi: 10.1016/S0140-6736(17)32250-X. PubMed DOI

[(accessed on 2 May 2022)]. Available online: Epidemie-COVID-19-v-Datech-Dopad-Na-Zdravotni-Peci-a-Prevenci.Pdf.

Hap K., Biernat K., Konieczny G. Patients with Diabetes Complicated by Peripheral Artery Disease: The Current State of Knowledge on Physiotherapy Interventions. J. Diabetes Res. 2021;2021:5122494. doi: 10.1155/2021/5122494. PubMed DOI PMC

Tappenden P., Chilcott J., Brennan A., Squires H., Stevenson M. Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework. Value Health. 2012;15:1127–1136. doi: 10.1016/j.jval.2012.07.008. PubMed DOI

Tappenden P., Chilcott J., Brennan A., Squires H., Glynne-Jones R., Tappenden J. Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value Health. 2013;16:542–553. doi: 10.1016/j.jval.2013.02.012. PubMed DOI

Lord J., Willis S., Eatock J., Tappenden P., Trapero-Bertran M., Miners A., Crossan C., Westby M., Anagnostou A., Taylor S., et al. Economic Modelling of Diagnostic and Treatment Pathways in National Institute for Health and Care Excellence Clinical Guidelines: The Modelling Algorithm Pathways in Guidelines (MAPGuide) Project. Health Technol. Assess. 2013;17:58. doi: 10.3310/hta17580. PubMed DOI PMC

Ezeofor V.S., Bray N., Bryning L., Hashmi F., Hoel H., Parker D., Edwards R.T. Economic Model to Examine the Cost-Effectiveness of FlowOx Home Therapy Compared to Standard Care in Patients with Peripheral Artery Disease. PLoS ONE. 2021;16:e0244851. doi: 10.1371/journal.pone.0244851. PubMed DOI PMC

Moussa Pacha H., Mallipeddi V.P., Afzal N., Moon S., Kaggal V.C., Kalra M., Oderich G.S., Wennberg P.W., Rooke T.W., Scott C.G., et al. Association of Ankle-Brachial Indices with Limb Revascularization or Amputation in Patients with Peripheral Artery Disease. JAMA Netw. Open. 2018;1:e185547. doi: 10.1001/jamanetworkopen.2018.5547. PubMed DOI PMC

Úmrtnostní Tabulky za ČR, Regiony Soudržnosti a Kraje. 2019–2020. [(accessed on 14 February 2022)]. Available online: https://www.czso.cz/csu/czso/umrtnostni-tabulky-za-cr-regiony-soudrznosti-a-kraje-i09aftm7w4.

Abry L., Weiss S., Makaloski V., Haynes A.G., Schmidli J., Wyss T.R. Peripheral Artery Disease Leading to Major Amputation: Trends in Revascularization and Mortality over 18 Years. Ann. Vasc. Surg. 2022;78:295–301. doi: 10.1016/j.avsg.2021.04.037. PubMed DOI

Vossen R.J., Vahl A.C., Leijdekkers V.J., Montauban van Swijndregt A.D., Balm R. Long-Term Clinical Outcomes of Percutaneous Transluminal Angioplasty with Optional Stenting in Patients with Superficial Femoral Artery Disease: A Retrospective, Observational Analysis. Eur. J. Vasc. Endovasc. Surg. 2018;56:690–698. doi: 10.1016/j.ejvs.2018.06.063. PubMed DOI

Nishibe T., Yamamoto K., Seike Y., Ogino H., Nishibe M., Koizumi J., Dardik A. Endovascular Therapy for Femoropopliteal Artery Disease and Association of Risk Factors with Primary Patency: The Implication of Critical Limb Ischemia and TASC II C/D Disease. Vasc. Endovasc. Surg. 2015;49:236–241. doi: 10.1177/1538574415614406. PubMed DOI

Antoniou G.A., Georgiadis G.S., Antoniou S.A., Makar R.R., Smout J.D., Torella F. Bypass Surgery for Chronic Lower Limb Ischaemia. Cochrane Database Syst. Rev. 2017;2017:CD002000. doi: 10.1002/14651858.CD002000.pub3. PubMed DOI PMC

Ambler G.K., Twine C.P. Graft Type for Femoro-Popliteal Bypass Surgery. Cochrane Database Syst. Rev. 2018;2018:CD001487. doi: 10.1002/14651858.CD001487.pub3. PubMed DOI PMC

Lane R., Harwood A., Watson L., Leng G.C. Exercise for Intermittent Claudication. Cochrane Database Syst. Rev. 2017;2017:CD000990. doi: 10.1002/14651858.CD000990.pub4. PubMed DOI PMC

Sartipy F., Sigvant B., Lundin F., Wahlberg E. Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. Eur. J. Vasc. Endovasc. Surg. 2018;55:529–536. doi: 10.1016/j.ejvs.2018.01.019. PubMed DOI

Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., Browner D. Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease. N. Engl. J. Med. 1992;326:381–386. doi: 10.1056/NEJM199202063260605. PubMed DOI

Vaidya A., Kleinegris M.-C., Severens J.L., Ramaekers B.L., ten Cate-Hoek A.J., ten Cate H., Joore M.A. Comparison of EQ-5D and SF-36 in Untreated Patients with Symptoms of Intermittent Claudication. J. Comp. Eff. Res. 2018;7:535–548. doi: 10.2217/cer-2017-0029. PubMed DOI

McDermott M.M., Tian L., Criqui M.H., Ferrucci L., Greenland P., Guralnik J.M., Kibbe M.R., Li L., Sufit R., Zhao L., et al. Perceived Versus Objective Change in Walking Ability in Peripheral Artery Disease: Results from 3 Randomized Clinical Trials of Exercise Therapy. JAHA. 2021;10:e017609. doi: 10.1161/JAHA.120.017609. PubMed DOI PMC

Darling J.D., McCallum J.C., Soden P.A., Korepta L., Guzman R.J., Wyers M.C., Hamdan A.D., Schermerhorn M.L. Results for Primary Bypass versus Primary Angioplasty/Stent for Lower Extremity Chronic Limb-Threatening Ischemia. J. Vasc. Surg. 2017;66:466–475. doi: 10.1016/j.jvs.2017.01.024. PubMed DOI PMC

Liang P., Li C., O’Donnell T.F.X., Lo R.C., Soden P.A., Swerdlow N.J., Schermerhorn M.L. In-Hospital versus Postdischarge Major Adverse Events within 30 Days Following Lower Extremity Revascularization. J. Vasc. Surg. 2019;69:482–489. doi: 10.1016/j.jvs.2018.06.207. PubMed DOI PMC

de Vries S.O., Visser K., de Vries J.A., Wong J.B., Donaldson M.C., Hunink M.G.M. Intermittent Claudication: Cost-Effectiveness of Revascularization versus Exercise Therapy. Radiology. 2002;222:25–36. doi: 10.1148/radiol.2221001743. PubMed DOI

van Rossum C.T.M., van de Mheen H., Witteman J.C.M., Hofman A., Mackenbach J.P., Grobbee D.E. Prevalence, Treatment, and Control of Hypertension by Sociodemographic Factors Among the Dutch Elderly. Hypertension. 2000;35:814–821. doi: 10.1161/01.HYP.35.3.814. PubMed DOI

Cífková R., Bruthans J., Adámková V., Jozífová M., Galovcová M., Wohlfahrt P., Krajčoviechová A., Petržílková Z., Lánská V., Poledne R., et al. The prevalence of major cardiovascular risk factors in the Czech population in 2006–2009. The Czech post-MONICA study. Cor Vasa. 2011;53:220–229. doi: 10.33678/cor.2011.050. DOI

Csémy L., Dvo Z., Fialová A., Kodl M., Malý M., Skývová M. Narodni Vyzkum Uzivani Tabaku a Alkoholu v Ceske Republice 2020. NAUTA; Prague, Czech Republic: 2021.

Schulte K.-L., Hardung D., Tiefenbacher C., Weiss T., Hoffmann U., Amendt K., Tepe G., Heuser L., Treszl A., Lau H.-J., et al. Real-World Outcomes of Endovascular Treatment in a Non-Selected Population with Peripheral Artery Disease—Prospective Study with 2-Year Follow-Up. Vasa. 2019;48:433–441. doi: 10.1024/0301-1526/a000798. PubMed DOI

Saxon R.R., Dake M.D., Volgelzang R.L., Katzen B.T., Becker G.J. Randomized, Multicenter Study Comparing Expanded Polytetrafluoroethylene–Covered Endoprosthesis Placement with Percutaneous Transluminal Angioplasty in the Treatment of Superficial Femoral Artery Occlusive Disease. J. Vasc. Interv. Radiol. 2008;19:823–832. doi: 10.1016/j.jvir.2008.02.008. PubMed DOI

van der Zaag E.S., Legemate D.A., Prins M.H., Reekers J.A., Jacobs M.J. Angioplasty or Bypass for Superficial Femoral Artery Disease? A Randomised Controlled Trial. Eur. J. Vasc. Endovasc. Surg. 2004;28:132–137. doi: 10.1016/j.ejvs.2004.04.003. PubMed DOI

Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study

Cost-effectiveness of diagnostic imaging modalities in symptomatic patients with lower limb peripheral arterial disease: discrete event simulation model